|
| |
|
| |
| EDITOR:
|
Neil Love, MD |
| |
|
| FEATURING: |
Mark Soloway, MD |
| |
CASE 1: 41-year-old man with a Gleason 6, T1 tumor
CASE 2: 66-year-old man with 4/9 positive nodes at prostatectomy
CASE 3: 57-year-old man with Gleason 9 tumor on TURP
CASE 4: 75-year-old man with a Gleason 6, cT2 tumor
Select Publications |
| |
|
| |
Paul Schellhammer,
MD, FACS |
| |
A personal perspective on prostate cancer
Immediate versus delayed androgen deprivation
Select
Publications |
| |
|
| |
Edward Messing, MD |
| |
Adjuvant hormonal therapy for men with node-positive
disease
Management of patients with positive surgical margins
at prostatectomy
The Early Prostate Cancer (EPC) trials in clinical practice
Management of patients with postprostatectomy PSA failure
Select Publications |
| |
|
| |
William A See, MD |
| |
The Early Prostate Cancer (EPC) trials
Counseling patients about the EPC data
Quality of life considerations with early hormonal therapy
Select Publications |
| |
|
| |
Nancy A Dawson, MD |
| |
Prostate Cancer Journal Club
| •
|
Pamidronate prevents bone loss associated with
androgen deprivation therapy |
| •
|
Zoledronic acid prevents skeletal - related adverse
events in men with metastatic hormone refractory
prostate cancer |
| •
|
Ten - year follow-up of low-risk prostate cancer
treated with brachytherapy |
| •
|
RTOG 8531: Long-term adjuvant androgen deprivation
following radiation therapy improves survival in
men with Gleason 8-10 prostate cancer |
| •
|
Bicalutamide as immediate thera py in prostate
cancer reduces the risk of disease progression |
| Management of men with
a rising PSA |
| CASE 5: 58-year-old man
with a Gleason 9 prostate cancer |
| CASE 6: 80-year-old man
with multiple responses to hormonal therapy |
| Select
Publications |
| |
| |
|
|
|
|
|
|
|
|
|
|
|
|
